Caribou Biosciences to Evaluate Strategic Alternatives
-- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs --
Covered in this story
Call it yourself
No calls on $CRBU yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Caribou Biosciences →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.